 | |
 | |
| Clinical data | |
|---|---|
| Pronunciation | la-TAN-oh-prost |
| Trade names | Xalatan, Xelpros, others |
| AHFS/ Drugs.com | Monograph |
| MedlinePlus | a697003 |
| License data |
|
|
Pregnancy category |
|
|
Routes of administration | Topical eye drops |
| Drug class | Prostaglandin analogue [1] |
| Legal status | |
| Legal status |
|
| Pharmacokinetic data | |
| Metabolism | Activation by ester hydrolysis, deactivation by beta oxidation |
| Onset of action | 3–4 hours |
| Elimination half-life | 17 minutes (plasma) |
| Duration of action | ≥ 24 hours |
| Excretion | Mainly via kidney |
| Identifiers | |
| |
| Chemical and physical data | |
| Formula | C26H40O5 |
| Molar mass | 432.593 g·mol−1 |
| 3D model ( JSmol) | |
| |
| |
| (verify) | |
Latanoprost, sold under the brand name Xalatan among others, is a medication used to treat increased pressure inside the eye. [1] This includes ocular hypertension and open angle glaucoma. [1] It is applied as eye drops to the eyes. [1] Onset of effects is usually within four hours, and they last for up to a day. [1]
Common side effects include blurry vision, redness of the eye, itchiness, and darkening of the iris. [1] Latanoprost is in the prostaglandin analogue family of medication. [1] It works by increasing the outflow of aqueous fluid from the eyes through the uveoscleral tract. [3]
Latanoprost was approved for medical use in the United States in 1996. [1] It is on the World Health Organization's List of Essential Medicines. [4] Latanoprost is available as a generic medication. [5] The wholesale cost in the developing world is about US$0.69–3.79 per 2.5 ml bottle. [6] In the United States a month of treatment costs less than US$25. [5] In 2017, it was the 81st most commonly prescribed medication in the United States with more than nine million prescriptions. [7] [8]
- ^ a b c d e f g h i j "Latanoprost". The American Society of Health-System Pharmacists. Archived from the original on 28 December 2016. Retrieved 8 December 2016.
- ^ "WHOCC - ATC/DDD Index". www.whocc.no. Archived from the original on 23 January 2021. Retrieved 16 September 2020.
- ^ Patel SS, Spencer CM (1996). "Latanoprost. A review of its pharmacological properties, clinical efficacy and tolerability in the management of primary open-angle glaucoma and ocular hypertension". Drugs Aging. 9 (5): 363–378. doi: 10.2165/00002512-199609050-00007. PMID 8922563.
- ^ World Health Organization (2019). World Health Organization model list of essential medicines: 21st list 2019. Geneva: World Health Organization. hdl: 10665/325771. WHO/MVP/EMP/IAU/2019.06. License: CC BY-NC-SA 3.0 IGO.
- ^ a b Hamilton, Richart (2015). Tarascon Pocket Pharmacopoeia 2015 Deluxe Lab-Coat Edition. Jones & Bartlett Learning. p. 413. ISBN 9781284057560.
- ^ "Latanoprost". International Drug Price Indicator Guide. Retrieved 8 December 2016.[ permanent dead link]
- ^ "The Top 300 of 2020". ClinCalc. Archived from the original on 12 February 2021. Retrieved 11 April 2020.
- ^ "Latanoprost - Drug Usage Statistics". ClinCalc. Archived from the original on 8 July 2020. Retrieved 11 April 2020.
|
| |
|
| |
| Clinical data | |
|---|---|
| Pronunciation | la-TAN-oh-prost |
| Trade names | Xalatan, Xelpros, others |
| AHFS/ Drugs.com | Monograph |
| MedlinePlus | a697003 |
| License data |
|
|
Pregnancy category |
|
|
Routes of administration | Topical eye drops |
| Drug class | Prostaglandin analogue [1] |
| Legal status | |
| Legal status |
|
| Pharmacokinetic data | |
| Metabolism | Activation by ester hydrolysis, deactivation by beta oxidation |
| Onset of action | 3–4 hours |
| Elimination half-life | 17 minutes (plasma) |
| Duration of action | ≥ 24 hours |
| Excretion | Mainly via kidney |
| Identifiers | |
| |
| Chemical and physical data | |
| Formula | C26H40O5 |
| Molar mass | 432.593 g·mol−1 |
| 3D model ( JSmol) | |
| |
| |
| (verify) | |
Latanoprost, sold under the brand name Xalatan among others, is a medication used to treat increased pressure inside the eye. [1] This includes ocular hypertension and open angle glaucoma. [1] It is applied as eye drops to the eyes. [1] Onset of effects is usually within four hours, and they last for up to a day. [1]
Common side effects include blurry vision, redness of the eye, itchiness, and darkening of the iris. [1] Latanoprost is in the prostaglandin analogue family of medication. [1] It works by increasing the outflow of aqueous fluid from the eyes through the uveoscleral tract. [3]
Latanoprost was approved for medical use in the United States in 1996. [1] It is on the World Health Organization's List of Essential Medicines. [4] Latanoprost is available as a generic medication. [5] The wholesale cost in the developing world is about US$0.69–3.79 per 2.5 ml bottle. [6] In the United States a month of treatment costs less than US$25. [5] In 2017, it was the 81st most commonly prescribed medication in the United States with more than nine million prescriptions. [7] [8]
- ^ a b c d e f g h i j "Latanoprost". The American Society of Health-System Pharmacists. Archived from the original on 28 December 2016. Retrieved 8 December 2016.
- ^ "WHOCC - ATC/DDD Index". www.whocc.no. Archived from the original on 23 January 2021. Retrieved 16 September 2020.
- ^ Patel SS, Spencer CM (1996). "Latanoprost. A review of its pharmacological properties, clinical efficacy and tolerability in the management of primary open-angle glaucoma and ocular hypertension". Drugs Aging. 9 (5): 363–378. doi: 10.2165/00002512-199609050-00007. PMID 8922563.
- ^ World Health Organization (2019). World Health Organization model list of essential medicines: 21st list 2019. Geneva: World Health Organization. hdl: 10665/325771. WHO/MVP/EMP/IAU/2019.06. License: CC BY-NC-SA 3.0 IGO.
- ^ a b Hamilton, Richart (2015). Tarascon Pocket Pharmacopoeia 2015 Deluxe Lab-Coat Edition. Jones & Bartlett Learning. p. 413. ISBN 9781284057560.
- ^ "Latanoprost". International Drug Price Indicator Guide. Retrieved 8 December 2016.[ permanent dead link]
- ^ "The Top 300 of 2020". ClinCalc. Archived from the original on 12 February 2021. Retrieved 11 April 2020.
- ^ "Latanoprost - Drug Usage Statistics". ClinCalc. Archived from the original on 8 July 2020. Retrieved 11 April 2020.